GlassScriptPhysician profile
Christopher M Donzell
NPI 1780932137
$3,263.41
in general payments reported to CMS, 2019-2025
28 companies · $674 in 2025
The $674 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $673 · 2022: $520 · 2023: $735 · 2024: $661 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,976 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,975.79 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $625.39 | 2021-2025 | |
| Novo Nordisk INC | $365.35 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $335.28 | 2021-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $300.17 | 2021-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $232.37 | 2021-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $192.02 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $127.72 | 2021-2025 | Evenity, Prolia, Repatha |
| Exact Sciences Corporation | $104.46 | 2023-2025 | Cologuard Collection Kit |
| Medtronic, INC. | $101.47 | 2021-2022 | |
| Esperion Therapeutics, INC. | $101.02 | 2021-2025 | Nexletol |
| Pfizer INC. | $86.35 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $79.38 | 2021-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.57 | 2021-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $68.72 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $63.01 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $61.19 | 2021-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.69 | 2025 | Caplyta |
| Mylan Specialty L.P. | $51.95 | 2023-2024 | Yupelri |
| Axsome Therapeutics, INC. | $46.08 | 2023-2025 | Auvelity |
| Dexcom, INC. | $30.76 | 2021 | |
| Sunovion Pharmaceuticals INC. | $30.06 | 2022 | |
| Novartis Pharmaceuticals Corporation | $25.78 | 2023 | |
| Sanofi-Aventis U.S. LLC | $22.60 | 2021 | |
| Radius Health, INC. | $18.52 | 2021 | |
| Vanda Pharmaceuticals INC. | $17.60 | 2021 | |
| Viatris Specialty LLC | $16.15 | 2025 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $14.04 | 2023 | Eliquis |
| Merck Sharp & Dohme LLC | $12.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Donzell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.